GO
Loading...

ARIAD Pharmaceuticals Inc

More

  • Feb 21- Ariad Pharmaceuticals Inc, which has been struggling with safety concerns involving its only approved drug, said it agreed to add two directors backed by its second-largest investor Sarissa Capital Management to its board.

  • Ariad to add two activist-backed directors to board Friday, 21 Feb 2014 | 7:55 AM ET

    Feb 21- Ariad Pharmaceuticals Inc, which has been struggling with safety concerns involving its only approved drug, said it agreed to add two directors backed by its second-largest investor Sarissa Capital Management to its board.

  • Dec 20- Ariad Pharmaceuticals Inc said it would resume selling its leukemia drug, Iclusig, in the United States, nearly two months after sales were halted due to safety concerns. Troubles started in early October when FDA placed a hold on enrollments for the drug's trials after a number of patients experienced blood clots and heart damage.

  • Ariad to resume sale of leukemia drug Iclusig Friday, 20 Dec 2013 | 10:26 AM ET

    Dec 20- Ariad Pharmaceuticals Inc said it will resume selling its leukemia drug, Iclusig, in the United States, nearly two months after sales were halted due to safety concerns. The U.S. Food and Drug Administration approved a revised label for the drug including a boxed warning, updated safety information and recommendations regarding dosing.

  • NEW YORK, Nov 22- U.S. stocks edged higher on Friday in the absence of economic data and ahead of a holiday-shortened week in the United States, a day after the Dow industrials closed above 16,000 for the first time.

  • NEW YORK, Nov 22- U.S. stocks were little changed on Friday amid a dearth of data and ahead of a holiday-shortened week in the United States, a day after the Dow industrials broke 16,000 for the first time.

  • *Time Warner Cable up as Charter nears bank deal for bid. NEW YORK, Nov 22- U.S. stocks were set to tick up at the open on Friday after the Dow industrials closed above 16,000 for the first time, amid a dearth of data and ahead of a holiday-shortened week in the United States.

  • Nov 22- Ariad Pharmaceuticals Inc said European regulators recommended the approval of its leukemia drug, Iclusig, whose U.S. sale has been suspended due to safety concerns, sending the company's shares up 24 percent in premarket trading.

  • Ariad adopts rights plan to protect tax assets Friday, 1 Nov 2013 | 10:54 AM ET

    Nov 1- Ariad Pharmaceuticals Inc adopted a shareholder rights plan to protect its tax credits, a day after sales of its flagship drug Iclusig were suspended due to safety concerns following an investigation by the U.S. health regulator.

  • *Ariad says working with FDA to find a way to bring drug back. WASHINGTON, Oct 31- Ariad Pharmaceuticals Inc has suspended sales of its leukemia drug Iclusig after an investigation by the U.S. Food and Drug Administration found that a significant number of patients developed life-threatening blood clots or narrowing of the veins.

  • Ariad's troubles started earlier this month when the FDA placed a partial hold on a late-stage trial after a number of patients taking Iclusig experienced blood clots and heart damage. The decision to suspend sales was taken in response to a request by the FDA, Ariad said in a statement on Thursday.

  • Oct 31- Ariad Pharmaceuticals Inc said it was suspending the sale of its blood cancer drug, Iclusig, barely two weeks after it stopped a late-stage trial of the drug due to safety concerns.

  • Midday movers: Google, Kansas City & more Friday, 18 Oct 2013 | 12:25 PM ET

    Take a look at some of Friday's midday movers:

  • After-Hours Buzz: Chevron, Ruby Tuesday & More Wednesday, 9 Oct 2013 | 5:03 PM ET

    Check out which companies are making headlines after the bell Wednesday:

  • Early movers: FDO, VVUS, MW, JCP, COST, AA & more Wednesday, 9 Oct 2013 | 7:51 AM ET

    Some of the names on the move ahead of the open.

  • Three tech laggards could have strong upside, Zack Safran of Ivy Science & Technology Fund says.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

    TheStreet.com offers up 13 biotech predictions for 2013.

  • How to Profit From Alexza Pharma FDA Ruling Wednesday, 19 Dec 2012 | 12:29 PM ET

    Here's how to profit from the coming Alexza FDA run down.

  • Early Movers: IR, IN, AAPL & More Monday, 10 Dec 2012 | 8:02 AM ET

    Some of the names on the move ahead of the open.

  • Ariad Pharma downgraded on gains over last year Tuesday, 23 Oct 2012 | 3:18 PM ET

    NEW YORK-- An Oppenheimer& Co. analyst downgraded shares of Ariad Pharmaceuticals Inc., saying the company's stock price already reflects potential approval for its leukemia drug ponatinib. Ferreiro said the Food and Drug Administration should approve ponatinib as a treatment for chronic myeloid leukemia in early 2013, as Ariad expects.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.